Sangamo to Launch First-in-human Clinical Trial Testing TX200 Cell Therapy in End-stage Renal Disease
News
The United Kingdom’s Medicines Healthcare Products Regulatory Agency (MHRA) has authorized the first-in-human clinical trial testing Sangamo Therapeutics’ TX200, a cell-based CAR-Treg therapy, in preventing rejection of transplanted kidneys in patients ... Read more